Is Morphic Holding a Buy?
On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its experimental therapy, MORF-057. That's a pretty significant pop for an under-the-radar biotech, especially based on data that comes from so early in a drug's clinical trial process.
Since then, the stock has sold off by nearly 33% from its highs. Can investors trust this biotech, which has no products on the market?
Image source: Getty Images.
Source Fool.com
